| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 51,429.0 | 50,711.0 |
| Profit before tax | 1,794.0 | 1,406.0 |
| Net income | 1,365.0 | 1,189.0 |
| EPS (diluted, $ a share) | $6.27 | $5.32 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +14.8% |
|---|---|
| Revenue, year on year | +1.4% |
| Operating margin | 2.5% |
10-Q filed with the SEC, NYSE: ELV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Elevance Health, Inc.: key numbers
- Share price
- $433.93Close, Nov 17
- Market cap
- $93.8B
- Shares outstanding
- 216.06MLatest SEC cover page
- Sector
- Finance
- Industry
- Hospital & Medical Service PlansSIC 6324
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Elevance Health, Inc.
All →Elevance Health Investor Meeting
Elevance Health officers are meeting with investors and analysts to reaffirm the company's full-year 2026 financial guidance. The company continues to expect adjusted shareholders’ earnings of at least $29.00 per diluted share and a benefit expense ratio of 90.2% plus or minus 50 basis points.
Elevance Health EVP & Chief Digital Info Ofr Ratnakar Lavu Sells $572K of Stock
Ratnakar Lavu, EVP & Chief Digital Info Ofr, sold 1,300 shares of Elevance Health, Inc. at $440.00 a share, worth $572K in total on Nov 5, 2026. Shares held after the trade: 14,849 (-8.1%).
- Value
- $572K
- Shares
- 1,300
- Price
- $440.00
- Role
- EVP & Chief Digital Info Ofr
- Holding change
- -8.1%
- Trade date
- Nov 5, 2026
Elevance Health EVP & CFO Mark Kaye Sells $4.66M of Stock
Mark Kaye, EVP & CFO, sold 10,584 shares of Elevance Health, Inc. at $434.00 to $447.19 a share (average $440.13) in 13 transactions, worth $4.66M in total on Oct 22, 2026. Shares held after the trade: 19,919 (-1.4%).
- Value
- $4.66M
- Shares
- 10,584
- Average price
- $440.13
- Role
- EVP & CFO
- Holding change
- -1.4%
- Trade date
- Oct 22, 2026
Elevance Health Earnings Call: Key Takeaways
New CFO Mark Kaye emphasizes a data-driven strategy focused on the Carelon flywheel and generative AI to sustain long-term earnings growth.
- Call
- Oct 21, 2026, 11:30 AM ET
Elevance Health Financial Results
Elevance Health reported Q3 2026 operating revenue of $50.4 billion and raised its full-year 2026 adjusted diluted EPS guidance to at least $29.00. The results were driven by improved operating performance in Medicare Advantage and Individual ACA, alongside growth in CarelonRx product revenue.
- Term
- Q3 2026
“Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business. We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75. By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value for our shareholders.”
Gail K. Boudreaux, President and Chief Executive Officer